Shares of PolyPid Ltd. (NASDAQ:PYPD – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the five brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $11.6667.
PYPD has been the topic of a number of recent research reports. Weiss Ratings raised PolyPid from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Wall Street Zen raised PolyPid from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th.
Get Our Latest Analysis on PolyPid
PolyPid Stock Performance
PolyPid (NASDAQ:PYPD – Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.12. On average, equities analysts forecast that PolyPid will post -1.34 EPS for the current fiscal year.
Institutional Investors Weigh In On PolyPid
A number of institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets raised its stake in shares of PolyPid by 56.1% during the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock valued at $32,000 after acquiring an additional 3,500 shares during the last quarter. HighTower Advisors LLC bought a new stake in shares of PolyPid in the fourth quarter worth $44,000. Jane Street Group LLC bought a new stake in shares of PolyPid in the fourth quarter worth $66,000. Renaissance Technologies LLC acquired a new stake in PolyPid in the first quarter valued at $81,000. Finally, XTX Topco Ltd increased its holdings in PolyPid by 50.0% in the fourth quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock valued at $142,000 after purchasing an additional 10,888 shares during the period. 26.47% of the stock is owned by institutional investors.
PolyPid Company Profile
PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.
Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.
Featured Articles
- Five stocks we like better than PolyPid
- AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus
- Gold and Silver Recovery—3 Precious Metals Stocks for H2 2026
- Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst
- Why Kroger’s Giant Eagle Deal Could Change Everything
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.
